GlassScriptPhysician profile
Jamie Williams
NPI 1477801918
$8,002.85
in general payments reported to CMS, 2019-2025
34 companies · $1,977 in 2025
The $1,977 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,509 · 2022: $1,553 · 2023: $1,530 · 2024: $1,433 · 2025: $1,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,824 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,824.43 |
| Education | $116.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,919.60 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,694.91 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $677.75 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $505.40 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $389.95 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $324.35 | 2022-2025 | |
| Celgene Corporation | $319.59 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $256.43 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $224.71 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $185.33 | 2021-2024 | Ocaliva |
| Pfizer INC. | $182.51 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $133.95 | 2024 | |
| Nestle Healthcare Nutrition INC. | $106.35 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $97.21 | 2023-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $89.04 | 2021-2023 | Dificid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $87.59 | 2021-2024 | Renflexis, Hadlima |
| Ferring Pharmaceuticals INC. | $86.26 | 2021-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $83.15 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $82.77 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $74.33 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $72.49 | 2021-2023 | Epclusa |
| Ironwood Pharmaceuticals, INC | $71.92 | 2021-2024 | Linzess |
| Evoke Pharma, INC. | $56.45 | 2021-2024 | |
| Vivus LLC | $56.18 | 2022-2025 | Pancreaze |
| Sandoz INC. | $42.54 | 2024 | Hyrimoz |
| Exact Sciences Corporation | $32.05 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $29.83 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $29.71 | 2021-2023 | Suflave |
| Amgen INC. | $19.54 | 2023 | Avsola, Amjevita |
| Celltrion USA INC. | $17.13 | 2023 | Yuflyma |
| Madrigal Pharmaceuticals | $16.33 | 2025 | Rezdiffra |
| Ethicon US, LLC | $14.96 | 2022 | |
| Intra-Sana Laboratories | $11.30 | 2021 | |
| Alnylam Pharmaceuticals INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.